Page 24 - Pharma Industry

Intas launches immuno-booster add-on drug to standard Covid-19 treatment

The formulation is the active biological component of black cumin; it fortifies the immunity and ensures higher success in fighting infection, the company says

USFDA issues 13 observations after inspection of Lupin arm's facility in US

Drug firm Lupin said the US health regulator has issued 13 observations after inspection of its subsidiary's Somerset facility in New Jersey

Alembic Pharma gets tentative USFDA nod for breast cancer treatment drug

Drug firm Alembic Pharmaceuticals said it has received tentative approval from the US health regulator for Palbociclib capsules, used to treat a certain type of breast cancer

US presidential election results may not impact Indian pharma industry

Europe, not India, will be the 1st target if US reduces import dependence: Experts

Cipla posts net profit of Rs 665 cr in Q2, income from ops grows 15%

The company's prescription biz grew 14% YoY supported by continued traction in the Covid portfolio

India's largest pharma IPO worth Rs 6,500 cr set to hit market next week

Fosun-owned Gland Pharma sets price band for its IPO at Rs 1,490-1,500 per share

Smaller pharma firms post faster domestic sales growth in September

Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth

PAG-led consortium to invest $70 mn for controlling stake in Anjan Drug

Private equity fund PAG is picking up a controlling stake in active pharmaceutical ingredient (API) maker Anjan Drug for over USD 70 million, sources said on Monday

Cardiac, vitamin drugs see pharma sales rebound with 4.5% growth in Sept

Industry says fresh prescriptions are picking up

PE/VC investments in pharma companies grow 3.5X in 2020, cross $1 bn mark

The reputation and relationships have helped pharma industry raise huge amounts of PE capital in 2020.

Dr Reddy's enters Rs 28,000 cr market with multiple sclerosis drug in US

The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement

Credit metrics of leading pharma companies to remain stable: ICRA

The global demand scenario for Indian pharmaceutical industry is largely expected to remain stable due to inelastic nature of prescription drugs, investment information agency ICRA has said.

Export boost to help pharma sector come out unscathed from Covid-19: CRISIL

Exports and domestic formulations account for an almost equal share in the Rs 2.8-trillion domestic pharma sector, CRISIL said

BPPI Q1 sales turnover up 94.21% to Rs 146.59 cr amid Covid-19 crisis

It had posted a sales turnover of Rs 75.48 crore in the corresponding first quarter of previous fiscal year, a statement by the ministry said

Lupin launches generic rheumatoid arthritis drug 'Leflunomide' in US market

Drug maker Lupin on Wednesday said it has launched Leflunomide tablets, used to treat rheumatoid arthritis, in the US market. The company has launched the product in 10 mg and 20 mg strengths after receiving the approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement. The product would be manufactured at drug maker's Pithampur (Unit I) facility in Madhya Pradesh, it added. The Mumbai-based company's product is the generic equivalent of Sanofi-Aventis US LLC's Arava tablets and is indicated for the treatment of adults with active rheumatoid arthritis (RA). As per IQVIA MAT June data, Leflunomide tablets had an annual sales of around USD 42 million in the US.

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse

The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more

Glenmark Q1 net jumps over two-fold, revenue up marginally at Rs 2,344.8 cr

"We focussed on controlling costs on all fronts and will continue with these efforts for the remaining part of the financial year," Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said

Cipla witnesses 3 senior-level exits including India biz CEO Nikhil Chopra

The company's rich legacy of care and strong sense of purpose rooted in a culture of meritocracy and high performance standards have made Cipla an employer of choice for several industry leaders

Will continue to focus on growing business faster than market: Sun Pharma

The company's strategy of developing the Specialty business as an additional growth engine has started delivering, with a gradual ramp up in specialty revenues, Shanghvi said

Pharma industry steps up to cure black marketing of Covid-19 drugs

Some firms are now considering starting their own distribution centres in major cities